This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge

ANNAPOLIS, Md., Sept. 13, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax ® next-generation anthrax vaccine program were presented at the 53 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax ® provides dose-dependent protection against lethal anthrax infection.

Dr. Sherry Crowe, Director, Immunology at PharmAthene, discussed the results in an oral presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax ® ) Provides Protection against Lethal Challenge with Bacillus anthracis in New Zealand White Rabbits."

Summary of SparVax ® Findings Reported

The need for newer anthrax vaccines based on modern vaccine technology, which offer the potential for improved safety, convenience and cost-effectiveness, is widely acknowledged.  SparVax ® is a next-generation anthrax vaccine based on recombinant protective antigen (rPA), the principal virulence factor of the organism, B. anthracis.  It is being developed for pre- and post-exposure protection against anthrax.

Previous non-clinical animal studies have demonstrated that immunization with SparVax ® stimulates the production of anti-PA antibodies that provide protection against anthrax infection. The objective of the current study was to provide further confirmation of the immunogenicity and efficacy of SparVax ® (manufactured in the U.S.) and determine the optimal dose range for protection.

In the current study, New Zealand White rabbits were administered escalating doses of SparVax ® ranging from 0.003 micrograms to 1.0 micrograms of rPA.  Control animals received either no immunization or were administered saline. Following immunization, the animals were challenged with B. anthracis spores (Ames strain).

The results demonstrated that SparVax ® was effective in providing protection against lethal inhalation anthrax challenge and resulted in no adverse clinical observations. In the study, immunization with SparVax ® stimulated a dose-dependent antibody response, which correlated with survival.

"PharmAthene is pleased to be working in partnership with the Biomedical Advanced Research and Development Authority (BARDA) towards our mutual goal of advancing novel, next-generation anthrax vaccines to address important national security initiatives," said Eric I. Richman, President and Chief Executive Officer.  "We look forward to continuing this progress and commencing a Phase 2 clinical trial of SparVax ® later this year."

Important Additional Information about the Proposed Merger

On August 1, 2013, PharmAthene filed with U.S. Securities and Exchange Commission (the "SEC") a current report on Form 8-K, which includes a copy of a merger agreement and related documents relating to a proposed merger involving Theraclone Sciences, Inc. ("Theraclone") and PharmAthene. On September 9, 2013, PharmAthene filed a registration statement on Form S-4 with the SEC, which contains a preliminary proxy statement/prospectus/consent solicitation and other relevant materials, and plans to file with the SEC other documents regarding the proposed transaction. Once the registration statement has been declared effective, the final joint proxy statement / prospectus / consent solicitation will be sent to the stockholders of PharmAthene and Theraclone in connection with the stockholder votes on matters relating to the proposed transaction.  The proxy statement/prospectus/consent solicitation contains information about PharmAthene, Theraclone, the proposed transaction, and related matters.

STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT / PROSPECTUS / CONSENT SOLICITATION (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY AS THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN, AS THE CASE MAY BE, IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER AND RELATED MATTERS. In addition to receiving the proxy statement/prospectus/consent solicitation and proxy card by mail, stockholders will also be able to obtain the proxy statement/prospectus/consent solicitation, as well as other filings containing information about PharmAthene, without charge, from the SEC's website ( http://www.sec.gov) or, without charge, by contacting Stacey Jurchison at PharmAthene at (410) 269-2610.  

No Offer or Solicitation



Stock quotes in this article: PIP 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,384.29 -40.56 -0.25%
S&P 500 1,860.82 -1.49 -0.08%
NASDAQ 4,081.9310 -4.2940 -0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs